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The results of a typical cost-effectiveness
(cost–utility) analysis are expressed by the
incremental cost-effectiveness ratio (ICER)
[1]: the money required to gain a quality-
adjusted life year (QALY) (i.e., one year with
best possible quality of life) at a population
level. The ICER concept is valuable for
choosing among diverse interventions com-
peting for limited resources. It was developed
primarily for societal or group-level deci-
sions, such as allocations of a fixed govern-
mental health budget, and consequently is
particularly helpful for health authorities and
other decision-makers who wish to prioritize
resource allocation in health care to numer-
ous interventions on diverse diseases across
whole systems. The major contribution of
ICER to inform population-level decisions is
even more obvious today, as health care
costs are escalating and rational choices need
to be made on how to contain cost without
compromising health outcomes at the soci-
etal level. However, conventional ICERs are
population-level tools, and fail to take into
account important inter-individual differenc-
es that might affect the value of a particular
intervention. The choice that maximizes the
population’s health or has the best ICER
overall is not always the same as the best
choice for a specific individual. Moreover,
the best choices may differ for different
i n d i v i d u a l s .T h e r ei st h u si n t e r e s ti nh o wt o
modify the ICER concept for applications in
individual decision-making [2,3]. In this
essay, we aim to contribute to the discussion
on how to use ICER and related metrics in a
way that would be more useful for decision-
making at the individual level, whether used
by clinicians or individual patients.
The Concept of Individualized
Cost-Effectiveness and
Individual Choices
By convention, the numerator of the
ICER is the difference in cost of care
between compared interventions. The
denominator is the corresponding differ-
ence in health outcomes (usually measured
in QALYs). The denominator combines
disparate kinds of information: diverse
health benefits and harms are summed
into a net health outcome measure.
As typically measured, the ICER ap-
praises the average experience with an
intervention. However, several investiga-
tors have pointed out that working with
averages is not good enough. According to
Kravitz et al. [4], ‘‘averages do not apply
to everyone.’’ As is now well-recognized,
averages are problematic for interpreting
clinical evidence, e.g., the results of
randomized trials, where treatment effects
(benefits, but also harms) are often hetero-
geneous, i.e., different for different types of
patients [5–7]. The same challenges arise
when one considers cost-effectiveness and
decision-making. After all, randomized
trials and other clinical studies typically
feed their data into decision and cost-
effectiveness models. Moreover, the gran-
ularity of the cost and outcomes per
patient may be important to convey, i.e.,
specifying separately the different out-
comes, so that clinicians and patients
may be better informed and able to make
better choices.
Sometimes there is no compelling
reason to distinguish different outcomes
rather than using a summary measure,
especially if all the outcomes are similar in
severity and consequences. For example,
consider two medicines that treat the
common cold. One of them reduces the
average duration of the cold by three days,
while the other reduces the average
duration by four days, but on average
the second one also causes one day of
headache as a side effect. As it happens,
the headaches are no better or worse than
having a cold. From the patient’s point of
view, both drugs decrease the duration of
symptomatic illness by three days, with no
meaningful difference between them.
However, lumping outcomes can be
problematic when two interventions, even
if they have identical mean effects, have
very different distributions of outcomes.
For example, suppose one intervention
reduces the duration of the cold by an
extra day relative to the other treatment,
but on rare occasions it causes side effects
that are either severe or prolonged, so the
net effect on health is identical, on
average. Then, some patients might
reasonably decide that they would prefer
the drug that is less effective most of the
time, rather than risk the small possibility
of becoming very ill if they were unlucky
enough to experience the major side
effect.
Heterogeneity in outcomes and costs
across patients may stem from both
observed (known) and unobserved (un-
known or unmeasured) sources. The
former arise from variation in well-known,
validated, measured characteristics that
predictably influence outcomes or costs.
For example, the benefit of an antibiotic
and the cost of treating an infection might
be well known to vary with the severity of
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causative organism. Heterogeneity from
unobservable sources essentially reflects
the variation in outcomes and costs that
occurs within a group of individuals with
otherwise identical observable characteris-
tics. This variation is due to chance or due
to predictors that are not discovered yet or
are not measured.
Situations Where the
Traditional ICER Alone Is
Insufficient
Table 1 lists situations where even
though the ICER is the same, the
individualized cost-effectiveness (and the
resulting choices) may vary. Note that this
distinction between requirements for indi-
vidual decision-making and population-
level ICERs is not a reflection of the
typical perspective question, i.e., whose
costs should be considered in the analysis
(the society’s, the payer’s, the insurer’s,
and so forth). We assume here a societal
perspective or the perspective of the
perfect insurer in the calculation of all
ICER estimates, as is standard practice in
cost-effectiveness analysis [8].
First, when the ICER is the same for
two treatments for different conditions,
each intervention may seem to be an
equally good investment. However, a
patient may have strong preferences for
one over the other. For example, consider
one intervention that improves outcomes
in a few very sick patients who would die
otherwise, but can live good-quality lives
with treatment; both the benefits and the
costs are very large. Another intervention
has an equally favorable ICER, but it
confers very small benefits to many
individuals who are not very sick at
baseline, with little cost per person. In
many circumstances, the former interven-
tion would be favored. Economists recog-
nize that individuals place a greater value
for the same absolute gains in life expec-
tancy as life expectancy becomes shorter,
all else being equal. For example, cadav-
eric donor liver transplantation has an
ICER of US$42,000/QALY [9] and in
many respects is more widely adopted
than intensive lifestyle intervention in
adults with impaired glucose tolerance,
which has at least as favorable an ICER
(one analysis gives even an ICER of
US$11,000/QALY [10]). Most of the
time, selecting between interventions for
different conditions is a challenge that
policy-makers, not individuals, face. How-
ever, individuals can face similar situa-
tions, particularly at different times in their
lives.
Second, two different interventions for
the same condition may have the same
ICER, and the same expected outcomes,
but the distributions of health outcomes
might differ—one might have greater
variance than the other. Some people
may be more risk-averse than others [11–
14]. Risk-averse people would sometimes
prefer an intervention that provided infe-
rior outcomes, on average, to an alterna-
tive that also had greater variance in
outcomes. For example, suppose that two
surgical interventions have the same ICER
of $25,000/QALY. One operation costs
$50,000 and confers 2.1 QALYs of benefit
against 0.1 QALYs of harms due to a
manageable problem that stems from the
surgery. Another more aggressive proce-
dure also costs $50,000 but confers 2.3
QALYs of benefit and, on average, 0.3
QALY of expected harm: 99% of the
patients get no harm, but 1% die during
the surgery and lose 30 years of life. Even
though both operations have the same
ICER, risk-averse patients may prefer to
avoid the aggressive surgery.
Finally, the best choice may vary with
an individual’s background health and
other, often highly personal, circumstanc-
es. Preferences over length of life may not
be a simple function of its length. For
example, a patient with late-stage meta-
static cancer may wish to live until a
landmark date, e.g., her daughter’s wed-
ding. The value of additional days of life
may decline sharply after the landmark
event. Among interventions with the same
ICER, the patient will choose the one that
maximizes the chances of remaining alive
until the wedding.
These limitations of conventional cost-
effectiveness analyses have long been
recognized, yet the focus on ICER values
averaged across a population is wide-
spread. Effective communication of indi-
vidualized analyses may require alterna-
tive approaches to presenting cost-
effectiveness information.
Possible Ways to Present
Individualized Cost-
Effectiveness
Box 1 lists different approaches to
individualizing cost-effectiveness.
Per Person Benefit and Cost
The reporting of the expected cost and
QALY gain or loss per person is already
widely considered standard practice for a
good cost-effectiveness analysis. However,
even recent papers don’t always report
these numbers transparently. To illustrate
how this works, suppose an analysis
simulates costs and expected outcomes
for 1,000,000 patients. Eventually, the
analysis shows that 500 QALYs are gained
by the new intervention versus a compar-
ator at an incremental cost of $5,000,000.
The ICER is $5,000,000/500=$10,000/
QALY. The per person cost is $5, for a
gain of 0.0005 QALYs.
Table 2 shows the traditional ICER and
calculated per person information from
eight examples of recent cost-effectiveness
analyses [15–22]. The individualized in-
formation is often easier to understand
when the QALYs are expressed in days,
i.e., in quality-adjusted life days (QALDs),
because for many interventions the in-
crease in QALYs is much less than one
QALY. As shown, the absolute magni-
tudes of the net benefit and of the cost per
person vary enormously across interven-
tions, far more than the variation in the
ICER. The average QALYs (or QALDs)
gained per person varies from 0.18 days
for screening for postnatal depression to
223 days for laparoscopic fundoplication
for gasto-esophageal reflux, a more than
1,200-fold difference. The cost per person
varies from about US$9 for rotavirus
Summary Points
N Cost-effectiveness analyses typically express their principal results as incremen-
tal cost-effectiveness ratios (ICERs).
N ICERs are useful in making decisions for allocation of resources at a population
level, but typical ICER measures have shortcomings when used for individual
decisions.
N For the same ICER, the cost-effectiveness may vary among individuals because
not everyone assigns the same priorities to specific outcomes, shares the same
attitudes toward risk, or faces the same distribution of expected outcomes.
N ICER information can be enhanced by providing additional metrics that
individualize cost-effectiveness analyses.
N These metrics include the per person net benefit and cost, subgroup ICER
estimates for observed measured sources of heterogeneity, and distributions of
outcomes and costs for unknown or unmeasured sources of heterogeneity.
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cation, an almost 300-fold difference.
Conversely, in these examples, differences
in traditional ICER are much smaller.
Observed Sources of Heterogeneity
Average results can be misleading for
many patients [23,24]. Whenever possible,
information should be tailored to identifi-
able subgroups with characteristics that
explain variability in outcomes and costs.
Costs and outcomes should be presented
for groups with different absolute benefits
(even if relative benefits, or relative risk
reduction from an intervention, are iden-
tical). Frequently authors are justifiably
reluctant to do so, particularly when the
information is derived from post-hoc
subgroup analyses of trial data. The extent
of desirable subgrouping depends on the
available evidence. There is a tipping
point at which stratifying outcomes too
finely and with limited evidence becomes
cumbersome and introduces too much
uncertainty to be useful for making
decisions. However, when well-validated
prognostic models are available or studies
using sufficient independent data support
the specific subgroup classifications
[25,26], cost–utility information can be
confidently individualized by level of
predicted risk and subgroup. For example,
a cost-effectiveness analysis of tissue plas-
minogen activator versus streptokinase for
thrombolysis in acute myocardial infarc-
tion has presented subgroup ICER esti-
mates for different locations of infarction
and different age groups, with up to 16-
fold differences across these subgroups
[27].
Unobserved Sources of
Heterogeneity
When heterogeneityinoutcomes orcosts
arises from unknown sources, every patient
who receives an intervention initially faces
the same distributionofpotentialoutcomes.
When heterogeneity matters, information
on the distribution of potential outcomes
and costs should also be presented, even
though we can’t predict which patient will
get the most benefit, and who will get the
rare but devastating adverse event. An
illustrative example of how to present this
information appears in Table 3.
The optimal way to present distribu-
tions depends on the type of variable. For
example, most continuous measures (in-
cluding cost) can be summarized with
means/medians and standard deviations
or interquartile ranges. Time-to-event
outcomes such as long-term survival are
conveniently represented by Kaplan-Me-
ier plots. Utility or quality weights can also
be plotted over time, with expected mean
values and variances thereof. Presenting
distributions in full detail requires space,
and their interpretation can be burden-
some, but both problems can be ad-
dressed, e.g., by online supplements that
include detailed explanatory material.
Societal versus Patient
Perspective
Thus far we have assumed a societal
perspective for the calculation of costs. We
should acknowledge that if patients don’t
have to pay for any of the health care costs
themselves, they may opt for the choice
that maximizes their net benefits regard-
less of the cost. However, in many health
systems, cost is taken into account and
limits the choices of individuals.
Even in countries with national health
systems that have minimized the role of
individual cost-sharing, individuals pay
growing shares of the costs of health and
health-related services out-of-pocket. Di-
rect-to-consumer advertisement, over-the-
counter interventions, and personalized
(e.g., genomic) testing are examples of
growing markets that try to appeal to
individuals who pay for services with their
own funds [28–30]. Because patients
spending their own money have a com-
pelling interest in the value of the services
they consume, cost-effectiveness analysis is
not solely the province of government or
corporate decision-makers. Whenever
costs and outcomes from the patient
perspective differ from those from the
population/societal perspective, costs and
outcomes should be reported from both
perspectives. This will greatly increase the
range of usefulness of the analysis. Across
different fields of economics, consumer
demand is an important consideration. It
is possible that policy-makers use ICER to
make decisions currently without informa-
tion that patients would find useful.
Table 1. Some situations where the traditional ICER does not necessarily suffice for individualized decision-making.
Situations Reasons
Same ICER, different individualized cost–utility
Different individuals with different conditions Priority may be given to major benefits
Different interventions for the same condition Variability in risk aversion
Different individuals with the same condition Variability in outcomes experienced
Same ICER, same individualized cost–utility, different choices
Similar individuals with the same condition Variability in risk aversion
Same individual Different background health
Different personal circumstances
doi:10.1371/journal.pmed.1001058.t001
Box 1. Approaches to Presenting Individualized Cost-
Effectiveness Analysis
N Per person benefit in QALYs or quality adjusted life days
N Per person cost
N Subgroup-specific estimates of per person benefit and per person cost for well-
documented and validated subgroups based on known sources of heteroge-
neity
N Distribution (extent of variance) of benefits overall and in subgroup-specific
estimates
N Distribution (extent of variance) in costs overall and in subgroup-specific
estimates
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Reference Ratio Description
Traditional ICER (US
Dollars/QALY)
Per Person Cost (US Dollars)
and Benefit (QALDs)
Finckh et al. [15] Early disease-modifying anti-rheumatic drug strategy versus
pyramid strategy in adults with very early rheumatoid arthritis
$4,849 Pay $1,450 to gain 110 days
Eckman et al. [16] Pharmacogenetic testing for personalized dosing of warfarin
during induction versus no genotyping in newly diagnosed
nonvalvular atrial fibrillation and no contraindications to warfarin
$171,750 Pay $369 to gain 0.78 days
Pletcher et al. [17] Full adherence to Adult Treatment Panel III guidelines for lipid
lowering versus current baseline adherence in ages 35–85 years
$42,000 Pay $328 to gain 2.83 days
Paulden et al. [18] Routine screening for postnatal depression in primary care versus
usual care in women assessed for postnatal depression,
Edinburgh postnatal depression scale cutoff point=16
$65,765 Pay $38.70 to gain 0.18 days
Latimer et al. [19] Celecoxib (200 mg) plus proton pump inhibitor versus etoricoxib
(30 mg) plus proton pump inhibitor in patients aged 55 years
with osteoarthritis
$17,192 Pay $126.60 to gain 3.38 days
Etoricoxib (30 mg) plus proton pump inhibitor versus diclofenac
(100 mg) plus proton pump inhibitor in patients aged 55 years
with osteoarthritis
$11,955 Pay $93 to gain 2.66 days
Diclofenac (100 mg) plus proton pump inhibitor versus no
treatment in patients aged 55 years with osteoarthritis
$11,142 Pay $31.70 to gain 1.04 days
Epstein et al. [20] Laparoscopic surgery versus continued medical management in
patients aged 45 and stable on gastro-esophageal reflux disease
medication
$4,237 Pay $2,586 to gain 223 days
Barton et al. [22] Dietary intervention plus strengthening exercises versus
strengthening exercises in adults aged 45 with self-reported knee
pain and BMI=28
$11,256 Pay $642 to gain 20.8 days
Dietary intervention plus strengthening exercises versus dietary
intervention in adults aged 45 with self-reported knee pain and
BMI=28
2$13,702 (cost-saving) Gain $192 and gain 5.11 days
Dietary intervention plus strengthening exercises versus leaflet
provision in adults aged 45 with self-reported knee pain and
BMI=28
$17,038 Pay $1,035 to gain 53.7 days
Rose et al. [21] Vaccination with two doses of rotavirus vaccine versus no
vaccination in India
$160 Pay $8.6 to gain 19.7 days
For cost-effectiveness using British pounds, a conversion of 1.6 US dollars per British pound has been used to convert values to US dollars. BMI, body mass index.
doi:10.1371/journal.pmed.1001058.t002
Table 3. Hypothetical example of different individual experiences for patients who do and do not experience different events
(benefit, harm, major harm, or other rare events).
Category of Patient
Experience Percent of Patients QALDs for Benefits/Harms Cost ( Dollars) Per Person Cost (Dollars) and Benefit (QALDs)
No benefit, no harm 80% 0/0 $10 Pay $10 for no gain
Benefit, no harm 10% 30/0 $8P a y $8 to gain 30 days
No benefit, harm 6% 0/5 $100 Pay $100 and lose 5 days
No benefit, major harm 2% 0/50 $1,000 Pay $1,000 and lose 50 days
Benefit, harm 0.75% 30/5 $80 Pay $80 to gain 25 days
Benefit, major harm 0.25% 30/50 $800 Pay $800 and lose 20 days
All other categories with
rare events
1% Varies per category,
average 5/10
Varies per category,
average $260
Varies per category, on average pay
$260 and lose 5 days
Average 3.35/1.56 $40 Pay $40 to gain 1.79 days
In the specific example, there are no known predictors that identify the patients who will experience any of these events. The intervention of interest confers a benefit in
one out of nine treated people, a minor harm in 6.8%, a major harm in 2.3%, and other events in 1%. On average, it costs $40 to gain 1.79 days. However, for the large
majority of patients (80%) who will experience no events, good or bad, the cost is $10 and there is no gain (or loss) at all. For patients in the 10% who will get the
benefit, without any harm, one has to pay only $8 per patient and each patient gains 30 days. Conversely, for patients in the 2% who experience the major harm and not
the benefit, one has to pay $1,000 per patient and each patient loses 50 days.
doi:10.1371/journal.pmed.1001058.t003
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has relevance to patients, even if they do
not bear costs directly, and to physicians
with an interest in ensuring the wise use of
resources. The costs of care are typically
hidden or unknown to patients and
physicians. Similarly, there may be a poor
understanding of what outcomes are really
at stake for an individual. Further studies
are needed to clarify whether provision of
individualized information influences the
behavior and choices of physicians and
patients.
Caveats
Once cost, benefits, and harms are
presented separately for different types of
patients, one can take an extra step and
directly incorporate personal preferences
in the calculations, i.e., placing different
weights on the same side effects and
benefits of therapy for different patients
[31,32]. One may even assign different
values to different time sequences of
beneficial and harmful events, e.g., by
reporting the healthy-years equivalents of
lifetime health profiles [33–35]. However,
personal weights for each type of cost and
outcome and healthy-years equivalents for
each of many possible complex lifetime
health profiles are often difficult to elicit.
Individualized analysis is not always
necessary or appropriate. First, the individ-
ualized cost-effectiveness information is
directly meaningful only for interventions
and strategies that are applied to a single
person and where the beneficial or harmful
impacts of the intervention do not extend
beyond the specific type of individual. For
example, full individualization cannot be
applied to a cost-effectiveness analysis of
modernization of adult critical care services
[36], where the intervention is made at the
level of a population service. Also, in cost-
effectiveness analyses of vaccination of boys
with human papilloma virus vaccine [37]
or of influenza vaccination strategies [38],
the intended benefits extend also to the
partners or contacts, respectively, of the
vaccinated individuals. In addition to the
personal stake for the vaccinated individu-
als, implications for the health of other
people may be substantial. Sometimes, the
cumulative impact on other people’s health
may far exceed the impact on the single
individual who gets such interventions.
Furthermore, estimates of individualized
cost-effectiveness, much like traditional
ICER estimates, are subject to errors in
the assumptions that feed into their calcula-
tions. These errors may stem from a lack of
evidence, poor representation of the evi-
dence, or even manipulations due to
conflicts of interest [39–41]. Erroneous
inferences may result from unrealistic mod-
eling of the decision process or unrealistic
estimates for the various benefits, harms,
and costs. Moreover, uncertainty in these
values [42] or even in risk aversion [43]
should not be underestimated. Sensitivity
analyses incorporating a range of values for
key parameters can be applied to the
individualized cost-effectiveness, much as
they are applied to the traditional ICER.
Concluding Comments
Cost-effectiveness analysis offers a foun-
dation for rational decision-making and
can be very helpful in making health care
more efficient and effective at the popula-
tion level [44]. Such analyses can often be
more useful for clinicians and for individ-
ual patients as well, when they individual-
ize the cost–utility information they pres-
ent. Individual-tailored information can
complement the traditional ICER.
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